Antiproton production and delivery for imaging and termination of undersirable cells

• US 20070225603A1
• Filed: 02/05/2007
• Published: 09/27/2007
• Est. Priority Date: 08/30/2001
• Status: Active Grant

• Current Assignee: HBAR Technologies LLC
• Original Assignee: HBAR Technologies LLC
• Inventors: Jackson, Gerald
• Granted Patent: US 8,109,865 B2
• Time in Patent Office: Days
• US Class Current: 600/436
• CPC Class Codes: A61B 6/037 Emission tomography
• CPC Class Codes: A61B 6/4258 for detecting non x-ray radiation, e.g. gamma radiation A61B6/037 takes precedence
• CPC Class Codes: A61B 6/583 using calibration phantoms
• CPC Class Codes: A61N 2005/1052 using positron emission tomography [PET] single photon emission computer tomography [SPECT] imaging
• CPC Class Codes: A61N 2005/1087 Ions; Protons
• CPC Class Codes: A61N 5/10 X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy A61N5/01 takes precedence
• CPC Class Codes: A61N 5/1048 Monitoring, verifying, controlling systems and methods
• CPC Class Codes: A61N 5/1079 Sharing a beam by multiple treatment stations
• CPC Class Codes: G21K 5/04 with beam-forming means
• CPC Class Codes: H05H 13/04 Synchrotrons

Abstract

Systems and methods for using antiprotons for terminating unwanted or undesirable cells which can be used in the treatment of conditions caused by the existence and/or proliferation of such undesirable cells. Such conditions include cardiovascular ailments, Parkinson'"'"'s disease, wet macular degeneration, endocrine disorders, dermatological ailments, and cancer. Because of the unique nature of antiprotons and their annihilation characteristics, the preferred antiproton delivery device (1010, 1015, 1030) embodiments further incorporate detector arrays (1050a), capable of detecting characteristic emissions in the course of treatment.

Claims

1. A method for treating a patient having a plurality of undesirable cells, comprising:

receiving a plurality of antiprotons in a trapped state;

inserting said antiprotons into an accelerator;

accelerating said antiprotons to a predetermined, therapeutic energy level;

forming a beam of antiprotons; and

exposing at least a portion of the plurality of the of undesirable cells to said beam.